Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00455221
Other study ID # 418-A-2209
Secondary ID
Status Completed
Phase Phase 1
First received March 31, 2007
Last updated May 31, 2012
Start date February 2008
Est. completion date November 2011

Study information

Verified date May 2012
Source Tehran University of Medical Sciences
Contact n/a
Is FDA regulated No
Health authority Iran: Ministry of Health
Study type Interventional

Clinical Trial Summary

The primary purpose of this study is to evaluate the safety of a peptide-gene vaccine against CML in patients under Imatinib treatment.

We will also perform some laboratory tests suggesting biological response.


Description:

- Patients will continue to take their current dose of Imatinib.

- Patients will undergo HLA-typing to define the HLA A, B, and DR.

- One constant dose of ten bcr-abl peptides (100μg each) will be administered subcutaneously in all patients triweekly for 8 doses.

- Four different doses of IL-12 and GM-CSF plasmids will be tested in this trial. The plasmids will be administered subcutaneously near the vaccination site 24 hours before vaccination.

- The first three patients will receive the lower dose of both IL-12 and GM-CSF plasmids. If this is well tolerated, then the next three patients will receive the lower dose of IL-12 plasmid and higher dose of GM-CSF plasmid. If this is well tolerated, then the next three patients will receive the higher dose of IL-12 and lower dose of GM-CSF plasmids. If this is well tolerated, then the next three patients will receive the higher dose of both IL-12 and GM-CSF plasmids. Once assigned to a dose, the patient will receive the same dose throughout their participation in this trial.

- Each vaccination may consist of one to several shots placed under the skin on the forearm, thigh or trunk area, and the sites will rotate per vaccination.

- During the clinic visit for vaccinations, blood tests will be drawn. If, during the course of therapy, side effects develop that the doctor feels pose a threat to the patient, treatment will be stopped.

- Patients will also undergo DTH skin tests before and after vaccination to see if an immune reaction is occurring at the injection site.

- Patients' lymphocytes will be tested before and after vaccination regarding IFN-γ and IL-4 production to assess immune system activation.

- During the course of treatment we will measure the effect the vaccine is having on the patients CML every three months by:

1. doing a bone marrow biopsy and aspirate analysis, and

2. measuring the amount of BCR-ABL that is detectable by RT-PCR in the patients' peripheral blood and bone marrow aspirate.


Recruitment information / eligibility

Status Completed
Enrollment 12
Est. completion date November 2011
Est. primary completion date December 2010
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Patients with Philadelphia chromosome positive CML who are:

1. of subtype b3a2

2. In first complete hematologic response;

3. have received imatinib for > 12 months of which the last 3 months were at a stable dose of at least 400 mg/day;

4. have PCR detectable BCR-ABL transcript by qRT-PCR, and

5. with persistent disease, as defined by <1 log reduction in peripheral blood or bone marrow BCR-ABL transcripts levels compared with a standardized baseline.

- Greater than or equal to 18 years in age

- No known infection with human immunodeficiency virus

- Physician and patient willingness to maintain the baseline dose of imatinib throughout the study period

- Written informed consent obtained from the patient

Exclusion Criteria:

- Female patients who are pregnant or breast feeding or adults of childbearing age who are not using adequate birth control.

- Current use of systemic immunosuppressive medications

- ALT or AST >3X Upper limit Normal

- Prior allogeneic stem cell transplantation

- Other experimental therapy within the past two months

- Prior participation in vaccine studies within the past six months

- Oxygen saturation of less than 95% at room air

- History of recent acute myocardial infarction, unstable angina, or pulmonary decompensation requiring hospitalization within the past 3 months.

- Concurrent and or uncontrolled psychiatric or medical condition which may interfere with the study completion.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Biological:
Bcr-abl multipeptide vaccine
The first three patients will receive the lower dose of both IL-12 and GM-CSF plasmids. If this is well tolerated, then the next three patients will receive the lower dose of IL-12 plasmid and higher dose of GM-CSF plasmid. If this is well tolerated, then the next three patients will receive the higher dose of IL-12 and lower dose of GM-CSF plasmids. If this is well tolerated, then the next three patients will receive the higher dose of both IL-12 and GM-CSF plasmids. Once assigned to a dose, the patient will receive the same dose throughout their participation in this trial
Genetic:
Cytokine gene adjuvant
Cytokine gene adjuvant

Locations

Country Name City State
Iran, Islamic Republic of Hematology-Oncology & SCT Research Center Tehran

Sponsors (1)

Lead Sponsor Collaborator
Tehran University of Medical Sciences

Country where clinical trial is conducted

Iran, Islamic Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary To assess safety of bcr-abl peptide vaccination in Ph+ or MRD CML patients At enroll in study and 3 months after intervention Yes
Secondary To measure the development of a molecular response to vaccination as measured by 1 log decrease in qRT-PCR BCR-ABL levels for at least 3 months; To measure the development of immune response following vaccination At enroll in study and 3 months after intervention No
See also
  Status Clinical Trial Phase
Terminated NCT00393380 - Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor Phase 2
Completed NCT00186342 - Sibling and Unrelated Donor Hematopoietic Cell Transplant in Hematologic Malignancies N/A
Completed NCT00759837 - Study Evaluating The Pharmacokinetics (PK) And Safety Of Bosutinib In Subjects With Liver Disease And In Healthy Subjects Phase 1
Completed NCT00538109 - An Open-Label, Multicenter, Expanded Access Study of Oral AMN 107 in Adult Patients With Imatinib (Glivec®/Gleevec®_ - Resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase N/A
Completed NCT00040105 - Zarnestra and Gleevec in Chronic Phase Chronic Myelogenous Leukemia Phase 1
Terminated NCT00176930 - Stem Cell Transplant for Hematological Malignancy N/A
Recruiting NCT01015742 - Unrelated Double Umbilical Cord Blood Units Transplantation Phase 2/Phase 3
Completed NCT00406393 - Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402) Phase 3
Completed NCT00246662 - Safety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the Treatment of Hematologic Malignancies Phase 1
Completed NCT00264160 - Efficacy and Safety of Oral AMN107 in Adults With Chronic Myelogenous Leukemia Resistant and/or Intolerant to Imatinib Mesylate Therapy Phase 2/Phase 3
Terminated NCT00306332 - T-cell and B-cell Depletion in Allogeneic Peripheral Blood Stem Cell Transplantation Phase 3
Terminated NCT00058747 - AG-858 in Patients Who Are Cytogenetically Positive After Treatment With Gleevec™ Phase 2
Active, not recruiting NCT00538447 - Prospective Database for Chronic Myelogenous Leukemia N/A
Terminated NCT01050946 - Hematopoietic Stem Cell Transplantation (HSCT) Using CD34 Selected Mismatched Related Donor and One Umbilical Cord Unit Phase 2
Completed NCT00034684 - Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia (Study P00701) Phase 1/Phase 2
Recruiting NCT04260022 - Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL Phase 1
Terminated NCT00167180 - Post Transplant Donor Lymphocyte Infusion Phase 2
Terminated NCT00449761 - Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia in Accelerated or Blast Phase Phase 2
Completed NCT00298987 - A Study of Dasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant of Imatinib Mesylate Phase 2
Completed NCT00763763 - Imatinib Mesylate With Vincristine and Dexamethasone in Acute Lymphoblastic Leukemias With BCR-ABL Positive Phase 2